August 13, 2024
If you attended /watched the recordings from the last two webinars, you might remember that Dr. Paul White and Dr. George Johnson highlighted the need to develop a conceptual framework to use genotoxicity data quantitatively for risk assessment. In this webinar, Marc Beal, PhD, a Research Scientist and Head of the Molecular and Applied Toxicology Section within the Food and Nutrition Directorate’s Bureau of Chemical Safety at Health Canada, showcases the advancements in interpreting in vitro concentration-response data for human health risk assessment. What you will learn:
- Advancements in the interpretation of in vitro concentration-response data for human health risk assessment.
- Organ-on-chip technologies that are serving to better recapitulate human and animal physiology in toxicity assessment
About our Speaker:
Marc A. Beal is a Research Scientist and Head of the Molecular and Applied Toxicology Section within the Food and Nutrition Directorate’s Bureau of Chemical Safety at Health Canada. He has over ten years of experience in toxicology and his current research focuses on developing non-animal models for studying the (geno)toxicity of food chemicals. He acquired his PhD from Carleton University in 2017 and his thesis research focused on developing novel approaches for studying mutagenesis. Before arriving at his current role, he worked as a senior scientific evaluator supporting risk assessments of legacy chemicals on Canada’s Domestic Substances List (2018-2021). In 2023, he was appointed as the first Junior Fellow in the Department of Biology at the University of Ottawa. He has published over 25 peer-reviewed scientific papers, and his work has been cited over 500 times. He is the current co-chair of the Genetic Toxicology Technical Committee in vitro working group, serves as chair of Genotoxicity Risk Assessment and Public Health special interest group within the Environmental Mutagenesis and Genomics Society, and he led a subgroup at the 8th International Workshop on Genotoxicity Testing that focused on developing strategies for the quantitative interpretation of in vitro genotoxicity data.
Abstract:
Genotoxicity assay results are traditionally interpreted using dichotomous hazard identification, whereby chemicals are qualitatively classified as genotoxic or non-genotoxic. However, genotoxicity is a bona fide toxicological endpoint, and the previous webinars presented by Dr. Paul White and Dr. George Johnson have highlighted why there is a need to develop a conceptual framework to use genotoxicity data quantitatively for risk assessment. Quantitative risk assessments are routinely performed using animal data; however, there is increasing awareness that non-animal in vitro approaches can serve as human-relevant alternatives. This webinar will showcase the advancements in the interpretation of in vitro concentration-response data for human health risk assessment. Attention will be given to in vitro-in vivo extrapolation methods that are required to estimate the external dose required to generate an internal steady-state concentration in plasma or tissue that is equivalent to the concentration that induces genotoxicity in vitro. This presentation will also touch on organ-on-chip technologies that are serving to better recapitulate human and animal physiology in toxicity assessment.
About ScitoVation:
ScitoVation helps clients assess chemical compound safety using innovative science, next-generation technology, and professional expertise. ScitoVation is known for partnership, flexibility, and proven success in its work to develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals and consumer products. A spin-off of the former The CIIT and The Hammer Institutes for Chemical & Drug Safety Sciences, ScitoVation is an industry leader of New Approach Methods (NAMS) for chemical/drug discovery & development in the rapidly evolving global regulatory landscape.